Boston ScientificBSX
About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Employees: 53,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
154% more first-time investments, than exits
New positions opened: 211 | Existing positions closed: 83
25% more repeat investments, than reductions
Existing positions increased: 603 | Existing positions reduced: 482
11% more funds holding in top 10
Funds holding in top 10: 35 [Q3] → 39 (+4) [Q4]
10% more capital invested
Capital invested by funds: $109B [Q3] → $120B (+$10.8B) [Q4]
8% more funds holding
Funds holding: 1,372 [Q3] → 1,479 (+107) [Q4]
2.23% more ownership
Funds ownership: 88.28% [Q3] → 90.51% (+2.23%) [Q4]
13% less call options, than puts
Call options by funds: $797M | Put options by funds: $912M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Barclays Matt Miksic 56% 1-year accuracy 22 / 39 met price target | 21%upside $125 | Overweight Maintained | 25 Apr 2025 |
Needham Mike Matson 42% 1-year accuracy 48 / 114 met price target | 12%upside $115 | Buy Maintained | 24 Apr 2025 |
RBC Capital Shagun Singh 48% 1-year accuracy 33 / 69 met price target | 17%upside $120 | Outperform Maintained | 24 Apr 2025 |
Truist Securities Richard Newitter 56% 1-year accuracy 28 / 50 met price target | 14%upside $117 | Buy Maintained | 24 Apr 2025 |
Evercore ISI Group Vijay Kumar 35% 1-year accuracy 15 / 43 met price target | 9%upside $112 | Outperform Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 36 articles about BSX published over the past 30 days
